In view of this, the current guidelines recommend that EGFR mutation testing should be performed in NSCLC patients with ADC or mixed-type tumors containing an adenocarcinomatous component, for example, ADSC, and is not necessary for patients with tumors lack of any adenocarcinomatous component, such as pure SqCC or pure LCC [19, 20]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.